| . | PATHWEIGH (N = 416) . | SOC (N = 165) . | P-value . |
|---|---|---|---|
| Age | |||
| Mean (SD) | 49.9 (15.9) | 48.9 (15.8) | 0.482 |
| Sex | |||
| Female | 246 (59.1%) | 56 (33.9%) | <0.001 |
| Male | 170 (40.9%) | 109 (66.1%) | |
| Race/ethnicity | |||
| Non-Hispanic White | 305 (73.3%) | 136 (82.4%) | 0.001 |
| Black | 12 (2.9%) | 3 (1.8%) | |
| Hispanic | 73 (17.5%) | 11 (6.7%) | |
| Other | 26 (6.2%) | 15 (9.1%) | |
| Insurance | |||
| Tricare | 30 (7.2%) | 6 (3.6%) | 0.038 |
| Commercial | 254 (61.1%) | 108 (65.5%) | |
| Medicare | 71 (17.1%) | 33 (20.0%) | |
| Colorado Medicaid | 35 (8.4%) | 4 (2.4%) | |
| Managed Medicare | 13 (3.1%) | 9 (5.5%) | |
| Other/Self-Pay | 13 (3.1%) | 5 (3.0%) | |
| Number of comorbidities (numeric) | |||
| Mean (SD) | 0.7 (0.8) | 0.4 (0.6) | <0.001 |
| Number of comorbidities | |||
| 0 | 203 (48.8%) | 113 (68.5%) | |
| 1–2 | 213 (51.2%) | 52 (31.5%) | |
| 3–5 | 14 (3.4%) | 2 (1.2%) | |
| Using oxygen or CPAP | 80 (19.2%) | 29 (17.6%) | |
| A1C (%) | |||
| Mean (SD) | 6.4 (1.5) | 6.3 (1.6) | |
| Missing | 254 | 124 | |
| TSH (mIU/L) | |||
| Mean (SD) | 3.8 (9.8) | 2.0 (1.3) | |
| Missing | 287 | 123 | |
| TG (mg/dl) | |||
| Mean (SD) | 181.8 (118.5) | 165.1 (126.9) | |
| Missing | 290 | 114 | |
| HDL (mg/dl) | |||
| Mean (SD) | 45.3 (12.8) | 45.6 (10.7) | |
| Missing | 290 | 114 | |
| ALT (U/L) | |||
| Mean (SD) | 38.1 (44.0) | 73.2 (78.0) | |
| Missing | 381 | 156 | |
| AST (U/L) | |||
| Mean (SD) | 30.1 (23.1) | 49.7 (56.9) | |
| Missing | 380 | 156 | |
| Binge eating | 21 (5.0%) | 2 (1.2%) | |
| PHQ-8 score | |||
| Mean (SD) | 1.8 (4.4) | 0.5 (1.6) | <0.001 |
| Missing | 11 | 0 | |
| PHQ-9 score | |||
| Mean (SD) | 6.9 (5.9) | 3.9 (4.0) | <0.001 |
| Missing | 239 | 110 | |
| Baseline BMI (kg/m2) | |||
| Mean (SD) | 36.0 (7.7) | 32.0 (7.0) | <0.001 |
| Weight loss (kg) | |||
| Mean (SD) | 1.2 (5.8) | 1.2 (5.1) | 0.991 |
| Weight loss rate (kg/month) | |||
| Mean (SD) | 0.2 (2.7) | 0.5 (1.8) | 0.212 |
| >5% weight loss | 59 (14.2%) | 21 (12.7%) | 0.691 |
| >10% weight loss | 15 (3.6%) | 8 (4.8%) | 0.485 |
| >15% weight loss | 7 (1.7%) | 2 (1.2%) | 1.000 |
| Follow-up duration (days) | |||
| Mean (SD) | 152.8 (99.7) | 155.4 (96.0) | 0.779 |
| Number of weight-prioritized visits | |||
| Median (Q1, Q3) | 1.0 (1.0, 2.0) | 1.0 (1.0, 1.0) | <0.001 |
| . | PATHWEIGH (N = 416) . | SOC (N = 165) . | P-value . |
|---|---|---|---|
| Age | |||
| Mean (SD) | 49.9 (15.9) | 48.9 (15.8) | 0.482 |
| Sex | |||
| Female | 246 (59.1%) | 56 (33.9%) | <0.001 |
| Male | 170 (40.9%) | 109 (66.1%) | |
| Race/ethnicity | |||
| Non-Hispanic White | 305 (73.3%) | 136 (82.4%) | 0.001 |
| Black | 12 (2.9%) | 3 (1.8%) | |
| Hispanic | 73 (17.5%) | 11 (6.7%) | |
| Other | 26 (6.2%) | 15 (9.1%) | |
| Insurance | |||
| Tricare | 30 (7.2%) | 6 (3.6%) | 0.038 |
| Commercial | 254 (61.1%) | 108 (65.5%) | |
| Medicare | 71 (17.1%) | 33 (20.0%) | |
| Colorado Medicaid | 35 (8.4%) | 4 (2.4%) | |
| Managed Medicare | 13 (3.1%) | 9 (5.5%) | |
| Other/Self-Pay | 13 (3.1%) | 5 (3.0%) | |
| Number of comorbidities (numeric) | |||
| Mean (SD) | 0.7 (0.8) | 0.4 (0.6) | <0.001 |
| Number of comorbidities | |||
| 0 | 203 (48.8%) | 113 (68.5%) | |
| 1–2 | 213 (51.2%) | 52 (31.5%) | |
| 3–5 | 14 (3.4%) | 2 (1.2%) | |
| Using oxygen or CPAP | 80 (19.2%) | 29 (17.6%) | |
| A1C (%) | |||
| Mean (SD) | 6.4 (1.5) | 6.3 (1.6) | |
| Missing | 254 | 124 | |
| TSH (mIU/L) | |||
| Mean (SD) | 3.8 (9.8) | 2.0 (1.3) | |
| Missing | 287 | 123 | |
| TG (mg/dl) | |||
| Mean (SD) | 181.8 (118.5) | 165.1 (126.9) | |
| Missing | 290 | 114 | |
| HDL (mg/dl) | |||
| Mean (SD) | 45.3 (12.8) | 45.6 (10.7) | |
| Missing | 290 | 114 | |
| ALT (U/L) | |||
| Mean (SD) | 38.1 (44.0) | 73.2 (78.0) | |
| Missing | 381 | 156 | |
| AST (U/L) | |||
| Mean (SD) | 30.1 (23.1) | 49.7 (56.9) | |
| Missing | 380 | 156 | |
| Binge eating | 21 (5.0%) | 2 (1.2%) | |
| PHQ-8 score | |||
| Mean (SD) | 1.8 (4.4) | 0.5 (1.6) | <0.001 |
| Missing | 11 | 0 | |
| PHQ-9 score | |||
| Mean (SD) | 6.9 (5.9) | 3.9 (4.0) | <0.001 |
| Missing | 239 | 110 | |
| Baseline BMI (kg/m2) | |||
| Mean (SD) | 36.0 (7.7) | 32.0 (7.0) | <0.001 |
| Weight loss (kg) | |||
| Mean (SD) | 1.2 (5.8) | 1.2 (5.1) | 0.991 |
| Weight loss rate (kg/month) | |||
| Mean (SD) | 0.2 (2.7) | 0.5 (1.8) | 0.212 |
| >5% weight loss | 59 (14.2%) | 21 (12.7%) | 0.691 |
| >10% weight loss | 15 (3.6%) | 8 (4.8%) | 0.485 |
| >15% weight loss | 7 (1.7%) | 2 (1.2%) | 1.000 |
| Follow-up duration (days) | |||
| Mean (SD) | 152.8 (99.7) | 155.4 (96.0) | 0.779 |
| Number of weight-prioritized visits | |||
| Median (Q1, Q3) | 1.0 (1.0, 2.0) | 1.0 (1.0, 1.0) | <0.001 |
ALT, alanine transaminase; AST, aspartate transaminase; CPAP, continuous positive airway pressure; HDL, high-density lipoprotein.
| . | PATHWEIGH (N = 416) . | SOC (N = 165) . | P-value . |
|---|---|---|---|
| Age | |||
| Mean (SD) | 49.9 (15.9) | 48.9 (15.8) | 0.482 |
| Sex | |||
| Female | 246 (59.1%) | 56 (33.9%) | <0.001 |
| Male | 170 (40.9%) | 109 (66.1%) | |
| Race/ethnicity | |||
| Non-Hispanic White | 305 (73.3%) | 136 (82.4%) | 0.001 |
| Black | 12 (2.9%) | 3 (1.8%) | |
| Hispanic | 73 (17.5%) | 11 (6.7%) | |
| Other | 26 (6.2%) | 15 (9.1%) | |
| Insurance | |||
| Tricare | 30 (7.2%) | 6 (3.6%) | 0.038 |
| Commercial | 254 (61.1%) | 108 (65.5%) | |
| Medicare | 71 (17.1%) | 33 (20.0%) | |
| Colorado Medicaid | 35 (8.4%) | 4 (2.4%) | |
| Managed Medicare | 13 (3.1%) | 9 (5.5%) | |
| Other/Self-Pay | 13 (3.1%) | 5 (3.0%) | |
| Number of comorbidities (numeric) | |||
| Mean (SD) | 0.7 (0.8) | 0.4 (0.6) | <0.001 |
| Number of comorbidities | |||
| 0 | 203 (48.8%) | 113 (68.5%) | |
| 1–2 | 213 (51.2%) | 52 (31.5%) | |
| 3–5 | 14 (3.4%) | 2 (1.2%) | |
| Using oxygen or CPAP | 80 (19.2%) | 29 (17.6%) | |
| A1C (%) | |||
| Mean (SD) | 6.4 (1.5) | 6.3 (1.6) | |
| Missing | 254 | 124 | |
| TSH (mIU/L) | |||
| Mean (SD) | 3.8 (9.8) | 2.0 (1.3) | |
| Missing | 287 | 123 | |
| TG (mg/dl) | |||
| Mean (SD) | 181.8 (118.5) | 165.1 (126.9) | |
| Missing | 290 | 114 | |
| HDL (mg/dl) | |||
| Mean (SD) | 45.3 (12.8) | 45.6 (10.7) | |
| Missing | 290 | 114 | |
| ALT (U/L) | |||
| Mean (SD) | 38.1 (44.0) | 73.2 (78.0) | |
| Missing | 381 | 156 | |
| AST (U/L) | |||
| Mean (SD) | 30.1 (23.1) | 49.7 (56.9) | |
| Missing | 380 | 156 | |
| Binge eating | 21 (5.0%) | 2 (1.2%) | |
| PHQ-8 score | |||
| Mean (SD) | 1.8 (4.4) | 0.5 (1.6) | <0.001 |
| Missing | 11 | 0 | |
| PHQ-9 score | |||
| Mean (SD) | 6.9 (5.9) | 3.9 (4.0) | <0.001 |
| Missing | 239 | 110 | |
| Baseline BMI (kg/m2) | |||
| Mean (SD) | 36.0 (7.7) | 32.0 (7.0) | <0.001 |
| Weight loss (kg) | |||
| Mean (SD) | 1.2 (5.8) | 1.2 (5.1) | 0.991 |
| Weight loss rate (kg/month) | |||
| Mean (SD) | 0.2 (2.7) | 0.5 (1.8) | 0.212 |
| >5% weight loss | 59 (14.2%) | 21 (12.7%) | 0.691 |
| >10% weight loss | 15 (3.6%) | 8 (4.8%) | 0.485 |
| >15% weight loss | 7 (1.7%) | 2 (1.2%) | 1.000 |
| Follow-up duration (days) | |||
| Mean (SD) | 152.8 (99.7) | 155.4 (96.0) | 0.779 |
| Number of weight-prioritized visits | |||
| Median (Q1, Q3) | 1.0 (1.0, 2.0) | 1.0 (1.0, 1.0) | <0.001 |
| . | PATHWEIGH (N = 416) . | SOC (N = 165) . | P-value . |
|---|---|---|---|
| Age | |||
| Mean (SD) | 49.9 (15.9) | 48.9 (15.8) | 0.482 |
| Sex | |||
| Female | 246 (59.1%) | 56 (33.9%) | <0.001 |
| Male | 170 (40.9%) | 109 (66.1%) | |
| Race/ethnicity | |||
| Non-Hispanic White | 305 (73.3%) | 136 (82.4%) | 0.001 |
| Black | 12 (2.9%) | 3 (1.8%) | |
| Hispanic | 73 (17.5%) | 11 (6.7%) | |
| Other | 26 (6.2%) | 15 (9.1%) | |
| Insurance | |||
| Tricare | 30 (7.2%) | 6 (3.6%) | 0.038 |
| Commercial | 254 (61.1%) | 108 (65.5%) | |
| Medicare | 71 (17.1%) | 33 (20.0%) | |
| Colorado Medicaid | 35 (8.4%) | 4 (2.4%) | |
| Managed Medicare | 13 (3.1%) | 9 (5.5%) | |
| Other/Self-Pay | 13 (3.1%) | 5 (3.0%) | |
| Number of comorbidities (numeric) | |||
| Mean (SD) | 0.7 (0.8) | 0.4 (0.6) | <0.001 |
| Number of comorbidities | |||
| 0 | 203 (48.8%) | 113 (68.5%) | |
| 1–2 | 213 (51.2%) | 52 (31.5%) | |
| 3–5 | 14 (3.4%) | 2 (1.2%) | |
| Using oxygen or CPAP | 80 (19.2%) | 29 (17.6%) | |
| A1C (%) | |||
| Mean (SD) | 6.4 (1.5) | 6.3 (1.6) | |
| Missing | 254 | 124 | |
| TSH (mIU/L) | |||
| Mean (SD) | 3.8 (9.8) | 2.0 (1.3) | |
| Missing | 287 | 123 | |
| TG (mg/dl) | |||
| Mean (SD) | 181.8 (118.5) | 165.1 (126.9) | |
| Missing | 290 | 114 | |
| HDL (mg/dl) | |||
| Mean (SD) | 45.3 (12.8) | 45.6 (10.7) | |
| Missing | 290 | 114 | |
| ALT (U/L) | |||
| Mean (SD) | 38.1 (44.0) | 73.2 (78.0) | |
| Missing | 381 | 156 | |
| AST (U/L) | |||
| Mean (SD) | 30.1 (23.1) | 49.7 (56.9) | |
| Missing | 380 | 156 | |
| Binge eating | 21 (5.0%) | 2 (1.2%) | |
| PHQ-8 score | |||
| Mean (SD) | 1.8 (4.4) | 0.5 (1.6) | <0.001 |
| Missing | 11 | 0 | |
| PHQ-9 score | |||
| Mean (SD) | 6.9 (5.9) | 3.9 (4.0) | <0.001 |
| Missing | 239 | 110 | |
| Baseline BMI (kg/m2) | |||
| Mean (SD) | 36.0 (7.7) | 32.0 (7.0) | <0.001 |
| Weight loss (kg) | |||
| Mean (SD) | 1.2 (5.8) | 1.2 (5.1) | 0.991 |
| Weight loss rate (kg/month) | |||
| Mean (SD) | 0.2 (2.7) | 0.5 (1.8) | 0.212 |
| >5% weight loss | 59 (14.2%) | 21 (12.7%) | 0.691 |
| >10% weight loss | 15 (3.6%) | 8 (4.8%) | 0.485 |
| >15% weight loss | 7 (1.7%) | 2 (1.2%) | 1.000 |
| Follow-up duration (days) | |||
| Mean (SD) | 152.8 (99.7) | 155.4 (96.0) | 0.779 |
| Number of weight-prioritized visits | |||
| Median (Q1, Q3) | 1.0 (1.0, 2.0) | 1.0 (1.0, 1.0) | <0.001 |
ALT, alanine transaminase; AST, aspartate transaminase; CPAP, continuous positive airway pressure; HDL, high-density lipoprotein.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
